{"id":460085,"date":"2026-02-11T00:30:00","date_gmt":"2026-02-10T23:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=460085"},"modified":"2026-02-11T07:34:10","modified_gmt":"2026-02-11T06:34:10","slug":"personalized-mrna-and-neoantigen-vaccines-in-oncology","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/personalized-mrna-and-neoantigen-vaccines-in-oncology\/","title":{"rendered":"Personalized mRNA and neoantigen vaccines in oncology"},"content":{"rendered":"\n

mRNA technology has experienced its global breakthrough as a result of the COVID-19 pandemic and has long been clinically established. In oncology, however, the actual translation is only now beginning. Opportunities and risks are closely linked – from precise immune activation to the challenge of tumor heterogeneity. Preclinical models demonstrate the potential of mRNA and neoantigen vaccines; clinical studies and congress reports show promising results in melanoma, pancreatic carcinoma, endometrial carcinoma and other tumor entities. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

mRNA technology has experienced its global breakthrough as a result of the COVID-19 pandemic and has long been clinically established. In oncology, however, the actual translation is only now beginning….…... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":460090,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Endometrial carcinoma, malignant melanoma and NSCLC in focus","footnotes":""},"category":[11508,11396,11406,11370,11460,11548,11503],"tags":[87948,87956,87942,20106,87952,87960,87950,21064,87944,87958,87946,87940,86116,87954],"powerkit_post_featured":[],"class_list":["post-460085","post","type-post","status-publish","format-standard","has-post-thumbnail","category-education","category-genetics","category-infectiology","category-oncology","category-prevention-and-health-care","category-rx-en","category-studies","tag-adjuvant-formulations","tag-cd8-t-cells","tag-combined-immune-strategies","tag-endometrial-cancer","tag-malignant-melanoma-and-nsclc","tag-neoantigen-identification","tag-neoantigen-vaccines-and-mrna-vaccines-synthetic-long-peptides-slps","tag-pancreatic-cancer","tag-patient-specific-tumor-mutations-neoantigens","tag-pd-1-blockade","tag-poly-ic","tag-tlr3","tag-tumor-microenvironment","tag-type-i-interferon-response","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-23 23:45:38","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":460095,"slug":"vaccins-personnalises-a-base-darnm-et-de-neoantigenes-en-oncologie","post_title":"Vaccins personnalis\u00e9s \u00e0 base d'ARNm et de n\u00e9oantig\u00e8nes en oncologie","href":"https:\/\/medizinonline.com\/fr\/vaccins-personnalises-a-base-darnm-et-de-neoantigenes-en-oncologie\/"},"it_IT":{"locale":"it_IT","id":460062,"slug":"vaccini-personalizzati-a-base-di-mrna-e-neoantigeni-in-oncologia","post_title":"Vaccini personalizzati a base di mRNA e neoantigeni in oncologia","href":"https:\/\/medizinonline.com\/it\/vaccini-personalizzati-a-base-di-mrna-e-neoantigeni-in-oncologia\/"},"pt_PT":{"locale":"pt_PT","id":460053,"slug":"vacinas-personalizadas-de-arnm-e-de-neoantigenios-em-oncologia","post_title":"Vacinas personalizadas de ARNm e de neoantig\u00e9nios em oncologia","href":"https:\/\/medizinonline.com\/pt-pt\/vacinas-personalizadas-de-arnm-e-de-neoantigenios-em-oncologia\/"},"es_ES":{"locale":"es_ES","id":460080,"slug":"vacunas-personalizadas-de-arnm-y-neoantigenos-en-oncologia","post_title":"Vacunas personalizadas de ARNm y neoant\u00edgenos en oncolog\u00eda","href":"https:\/\/medizinonline.com\/es\/vacunas-personalizadas-de-arnm-y-neoantigenos-en-oncologia\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/460085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=460085"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/460085\/revisions"}],"predecessor-version":[{"id":460096,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/460085\/revisions\/460096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/460090"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=460085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=460085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=460085"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=460085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}